Frequent occurrence of undiagnosed pelvic inflammatory disease in remote communities of central Australia by Silver, Bronwyn J. et al.
Research
Bronwyn J Silver
BNurs, GradDipMID, MPH,
Research Fellow1
Janet Knox
MMed(STD/HIV),
DTM&H, FAChSHM,
Sexual Health Physician2
Kirsty S Smith
GDipCommNurs,
GDipEd, MPH,
Sexual Health
Nurse Consultant2
James S Ward
BA,
Deputy Director3
Jacqueline Boyle
FRANZCOG, MPH, PhD,
Obstetrician and
Gynaecologist and
Senior Research Fellow4
Rebecca J Guy
BAppSc, MAppEpid, PhD,
Post Doctoral
Research Fellow2
John Kaldor
PhD,
Professor of Epidemiology
and Head of Public Health
Interventions Research
Program2
Alice R Rumbold
BSc(Hons), MPH, PhD,
Senior Research Fellow1,5
1 Epidemiology and Health
Systems, Menzies School
of Health Research,
Alice Springs, NT.
2 The Kirby Institute
for Infection and
Immunity in Society, University
of New South Wales,
Sydney, NSW.
3 Preventative Health,
Baker IDI Heart and
Diabetes Institute,
Alice Springs, NT.
4 Jean Hailes Foundation
for Women’s Health,
Monash University,
Melbourne, VIC.
5 Obstetrics and Gynaecology,
University of Adelaide,
Adelaide, SA.
bronwyn.silver@
menzies.edu.au
MJA 2012; 197: 647–651
doi: 10.5694/mja11.11450
Editorial p 597
Research p 642Frequent occurrence of undiagnosed 
pelvic inflammatory disease in remote 
communities of central AustraliaThe Medical Journal of Australia ISSN: 0025-
729X 3/17 December 2012 197 11/12 647-651
©The Medical Journal of Australia 2012
www.mja.com.au
Research
The study was conducted in fiv
mary health care centres in re
central Australia, where high p
lences of gonorrhoea and chla
have been recorded in comm
wide STI screening programs.
ticipating services included go
ment and Aboriginal commuObjective:  To assess the extent of diagnosed and undiagnosed pelvic 
inflammatory disease (PID) in Aboriginal women in remote central Australia.
Design, setting and subjects:  Retrospective cross-sectional study in five 
remote central Australian primary health care centres. Medical records of all 
resident Aboriginal women aged 14–34 years were examined. Data were from 
presentations with documented lower abdominal pain, excluding other causes, 
for 2007–2008.
Main outcome measures:  PID investigations undertaken, PID diagnoses made, 
recommended treatment, and presentations meeting the guideline criteria for 
diagnosing PID based on pelvic examination, symptom profile or history.
Results:  Of 655 medical records reviewed, 119 women (18%) presented 224 
times with lower abdominal pain. Recommended investigations to diagnose PID 
were infrequently undertaken: bimanual examination (15 cases [7%]); testing 
for gonorrhoea and chlamydia (78 [35%]); and history taking for vaginal 
discharge (59 [26%]), intermenstrual bleeding (27 [12%]) and dyspareunia 
(17 [8%]). There were 95 presentations (42%) consistent with guidelines to 
diagnose PID, most (87 [39%]) based on symptom profile and history. Of these, 
practitioners made 15 diagnoses of PID, and none had the recommended 
treatment documented.
Conclusion:  Pelvic inflammatory disease occurred frequently among Aboriginal 
women in central Australia during the study period but was vastly 
underdiagnosed and poorly treated. Undiagnosed or inadequately treated 
PID leads to poorer reproductive health outcomes in the long term. Increased 
awareness of PID symptoms, diagnosis and treatment and a revision of the 
guidelines is needed to improve detection and management of PID in this high-
risk setting.
Abstractel
(P
rep
ing ectopi
P vic inflammatory diseaseID) is associated with severeroductive sequelae, includ-
c pregnancy and tubal factor
infertility.1,2 It has an infectious origin,
and chlamydia and gonorrhoea are
important causes of PID in popula-
tions where sexually transmissible
infections (STIs) occur at high levels.1,3
Early detection and effective man-
agement of PID in primary care set-
tings can prevent complications and
hospitalisation.4 Under Australian and
international clinical guidelines,5-7 cli-
nicians are encouraged to have a high
index of suspicion and a low thresh-
old for treatment when a young
woman presents with lower abdomi-
nal pain, after exclusion of other
causes. Treatment includes a 2-week
broad-spectrum antibiotic regimen to
cover the likely causative pathogens.
In the Northern Territory, hospitali-
sation for acute PID occurs at nine
times the rate among Aboriginal and
Torres Strait Islander women, com-
pared with non-Indigenous women,8
and many remote communities have
been found to have an increased pre-
valence of bacterial STIs.9 These find-
ings suggest that Aboriginal women
may not be receiving effective primary
health care for diagnosis and treat-
ment of PID. To assess the extent of
PID and its management in remote
primary health care centres, we
undertook a retrospective study of
women presenting with lower
abdominal pain, which is the most
common symptom of PID.
Methods
e pri-
mote
reva-
mydia
unity-
9 Par-
vern-
nity-
controlled facilities. Health care in
these centres is routinely provided by
remote area nurses (RANs), with
medical advice available by tele-
phone; general practitioners, who
attend monthly; and obstetrics and
gynaecology health professionals
who provide a 6-monthly clinic. Few
centres employ a full-time GP. At the
time of the study, these services used
a combination of paper-based and
electronic systems to record patient
information.
We examined all available medical
records of resident Aboriginal women
aged 14–34 years, to identify all
instances of women presenting with
lower abdominal pain from 1 January
2007 to 31 December 2008 at partici-
pating centres. We excluded women
for whom gastroenteritis, trauma,
miscarriage or pregnancy (including
early labour) were documented as the
cause of lower abdominal pain.
For each presentation, we obtained
information including:
• the woman’s age
• results of gonorrhoea or chlamydia
tests the woman had had during 2007
and 2008
• the woman’s history of PID
• signs of PID when a bimanual
examination was undertaken
• documentation of presence or
absence of other signs and symptoms
associated with PID (eg, vaginal dis-
charge, dyspareunia and intermen-
strual bleeding)
• the diagnosis documented by the
practitioner
• the treatment administered
• the attending practitioner type.
In addition to reviewing the medical
records at the centres, we obtained
information on gonorrhoea and
chlamydia testing conducted in the
participating centres from a database
at the NT Centre for Disease Control,
which receives all results of STI testing
direct from pathology laboratories.
For each included case of lower
abdominal pain, the documented
clinical assessments and their out-647MJA 197 (11/12) · 3/17 December 2012
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teria for diagnosing PID which are
specified in guidelines applicable at
the time of the study (Box 1).10,11 We
identified presentations that were
documented as having met the crite-
ria for diagnosing PID and, from
these, calculated the proportion with
a documented diagnosis of PID.
Presentations with documentation
that met the guideline criteria, but that
had not had a PID diagnosis docu-
mented in the medical record, were
considered undiagnosed PID. For pres-
entations in which PID was diagnosed,
we assessed practitioner adherence to
the recommended PID treatment (Box
2),10,11 and calculated the proportion of
presentations with a documented
diagnosis of PID for which the correct
treatment was prescribed.
Proportions, means and medians
were used to summarise the charac-
teristics of presenting women, practi-
tioner types, assessments undertaken,
diagnoses made and treatments
administered. All analyses were per-
formed using Stata, version 10.1
(StataCorp).
Consultations with the relevant
local stakeholders and communities
were undertaken before the study.
Ethics approval was granted by the
Central Australian Human Research
Ethics Committee, the Human
Research Ethics Committee of the
Northern Territory Department of
Health and Menzies School of Health
Research and its associated Aboriginal
Ethics Sub Committee, and the Uni-
versity of New South Wales Human
Research Ethics Committee. Approval
was obtained from the Northern Terri-
tory Department of Health and Fami-
lies and from the boards of the
participating Aboriginal community-
controlled health services.
Results
Characteristics of participating 
women
Participating health centres held the
medical records of 655 eligible women
that were available for review. Of
these, after the exclusion of other
causes of abdominal pain, 119 women
(18%) presented 224 times with lower
abdominal pain during the study
period 2007–2008 (range, 1–13 pres-
entations per woman; median, two
presentations; mean time between
presentations, 65 days). The median
age was 25.3 years (interquartile
range, 20.6–29.6 years). A record of
con f ir med  gonor rhoea  and/o r
chlamydia infection within 90 days
before or after the presentation date
was found for 62 presentations (28%)
(38 women). A record of any STI in
the year before presentation was doc-
umented for 78 presentations (35%)
(46 women), and a history of PID was
noted in four presentations (2%)
(three women).
Characteristics of health 
practitioners
Of the presentations, 162 (72%) were
managed by an RAN, who referred to
a GP at 13 presentations (6%). Care
was provided by Aboriginal health
workers for 14 presentations (6%), by
GPs for 14 (6%), by sexual or
women’s health specialists for eight
(4%), and by medical students for two
(1%). For 23 presentations (10%), the
practitioner type was not recorded.
Clinical assessment
Based on available records, the 224
presentations of 119 women with
lower abdominal pain led to a biman-
ual examination in 15 presentations
(7%) (13 women); and documen-
tation of the presence or absence of
vaginal discharge, intermenstrual
bleeding and dyspareunia in 59 pres-
entations (26%) (41 women), 27 pres-
entations (12%) (22 women) and 17
presentations (8%) (17 women)
respectively (Box 3). There were posi-
tive findings recorded for about half
the bimanual examinations, and less
than a quarter of the symptom assess-
ments (Box 3). In addition, testing for
gonorrhoea and chlamydia was
undertaken in 78 presentations (35%)
(63 women), with 21% of gonorrhoea
test results positive and 15% of
chlamydia test results positive.
Overall, 35 (16%) of the 224 pres-
entations with lower abdominal pain
had a PID diagnosis recorded. These
occurred in 29 women (six women
were diagnosed with PID on two
occasions). Of these presentations,
the attending practitioner type was
predominantly an RAN (for 26 pres-
entations). Practitioner type was a GP
for three presentations, a women’s or
sexual health specialist for three pres-
entations and was unrecorded for
three presentations. The frequency of
investigations undertaken was similar
in presentations with a recorded diag-
nosis of PID and no diagnosis.
Presentations documented as 
meeting criteria for PID
Of the 224 presentations (119
women) with lower abdominal pain,
we identified 95 presentations (42%)
(54 women) documented as having
met the criteria for diagnosing PID
according to the guidelines. Of these,
1 Criteria for diagnosis and treatment of pelvic inflammatory disease according 
to the clinical guidelines for Northern Territory remote health practitioners, 
2007–200810,11
If a bimanual examination is conducted:
• lower abdominal pain and cervical excitation or adnexal tenderness or uterine 
tenderness
If a bimanual examination is not conducted:
• lower abdominal pain and vaginal discharge; or
• no vaginal discharge and lower abdominal pain, and aged 14–34 years and 
dyspareunia or intermenstrual bleeding or history of sexually transmitted infection or 
pelvic inflammatory disease in the past year ◆
2 Recommended treatment regimen for pelvic inflammatory disease according 
to the clinical guidelines for Northern Territory remote health practitioners, 
2007–200810,11
Day 1:
• ceftriaxone 250 mg intramuscularly or intravenously (single dose), and
• azithromycin 1 g orally (single dose)
Day 2:
• doxycycline 100 mg orally twice a day for 14 days (doxycycline course can be 
omitted if azithromycin is administered on day 7), and
• metronidazole 400 mg orally twice a day for 14 days
Day 7:
• azithromycin 1 g orally (single dose) ◆11/12) · 3/17 December 2012
Researcheight presentations (seven women)
met the criteria based on the detec-
tion of cervical excitation and/or adn-
exal or uterine tenderness on pelvic
examination, 11 presentations (seven
women) met the criteria based on the
presence of vaginal discharge, and 76
presentations (44 women) met the
criteria based on a combination of
risk factors and the presence of dys-
pareunia or intermenstrual bleeding
(Box 4).
Among the 95 presentations (54
women), there were 15 presentations
(11 women) recorded by the practi-
tioner as being a diagnosis of either
PID alone (seven presentations, six
women) or PID in conjunction an STI
(two presentations, one woman) or
urinary tract infection (six presenta-
tions, six women). The remainder
were recorded as a urinary tract
infection (25 presentations, 25
women), a sexually transmissible
infection (12 presentations, 10
women), a condition unrelated to
infection (20 presentations, 11
women) or  had  no diagnosi s
recorded (28 presentations, 11
women); in some of these presenta-
tions a dual diagnosis was recorded.
Conversely, there were 20 presenta-
tions (19 women) out of the 224 that
were diagnosed by the practitioner as
PID, but had no documented evi-
dence of PID other than lower
abdominal pain (data not shown).
Of the 95 presentations, most (65)
were managed by an RAN only, seven
were referred to a GP, six were seen by
a GP only, six by an Aboriginal health
worker only, four by a sexual or
women’s health specialist only, and in
seven presentations, the practitioner
type was unknown. The rate of diag-
nosis did not differ by practitioner
type (data not shown).
Treatment for PID
Correct treatment for PID, as specified
in guidelines, was not administered in
any of the 95 presentations (54
women) documented as having met
the criteria for PID. Of the 35 presen-
tations for which a PID diagnosis was
recorded, none were documented to
have received the recommended
treatment (Box 2). In 12, correct medi-
cations were administered but either
one was omitted or the wrong dose,
duration or frequency of medication
was prescribed; in 18, a single dose of
azithromyc in,  amoxycil l in  and
probenecid (the recommended syn-
dromic treatment for gonorrhoea and
chlamydia) was recorded; in four, pain
relief only was recorded; and in one
presentation, no treatment was
recorded (data not shown).
Discussion
Our study is the most comprehensive
assessment undertaken of PID diag-
nosis and management among Abori-
ginal women. In a community
sample, we found that around one in
10 women in the age group at highest
risk for PID presented to a primary
health care centre with symptoms and
investigation results consistent with
PID at least once in a 2-year period.
Most presentations were not investi-
gated according to clinical guidelines
for PID. As a result, cases likely to be
PID were frequently missed and those
that were detected were not treated
according to guidelines. These epi-
sodes represent missed opportunities
to prevent the long-term adverse
reproductive outcomes associated
with PID.
Our study is by no means the first
to find that PID management
presents a challenge in primary care.
An Australian study in an urban sex-
ual health clinic found substantial var-
iation among doctors in the number
of PID diagnoses made compared
with diagnoses of genital warts,12 a
variation probably attributable to
underdiagnosis of PID by some prac-
titioners. A study in the United States
reviewed emergency department
records and found that only one-third
of patients diagnosed with PID were
prescribed antibiotics according to
guidelines.13
Given the very high levels of PID
indicated in our study and in earlier
research from the NT,14,15 it is impor-
tant to consider the reasons for the
lack of guideline adherence observed
in this study. Although provision of
better or more accessible information
has improved guideline adherence
internationally16,17 it would probably
not, on its own, change the situation
markedly in central Australia, where
PID-related education sessions have
been widely available to both GPs and
RANs for the past decade, as part of
in-service training, and guidelines
prompt clinicians to “think PID” in all
relevant sections.10,18
A greater impact on PID manage-
ment may arise through rethinking the
guidelines to better reflect the clinical
realities of remote primary health care.
The current guidelines for diagnosis
begin with the implication that a
definitive diagnosis requires a biman-
ual pelvic examination, a procedure
that many remote GPs and RANs may
not be comfortable to readily perform,
either because they do not have the
training, or, if they do, they have lim-
ited recent experience. Furthermore,
the individual clinical signs and symp-
toms stated in the guidelines lack sen-
sitivity and specificity.19
A more pragmatic approach to PID
diagnosis in this high-risk setting is
based on the presence of lower
abdominal pain, after the exclusion
of other causes in sexually active
women aged 14–34 years. Additional
information that would be of value
includes younger age and back-
ground community STI prevalence,
rather than specific signs and
symptoms20 or individual sexual his-
tory. While this strategy would result
in some women being unnecessarily
treated for PID, it is consistent with
the requirement for a high suspicion
3 Clinical findings in women aged 14–34 years with lower abdominal pain, 
2007–2008 (n = 224)
Clinical assessment Undocumented (%)
Documented (%) 
[positive findings]
Bimanual pelvic examination signs
Cervical excitation 209 (93%) 15 (7%) [8]
Adnexal/uterine tenderness 214 (96%) 10 (4%) [6]
Symptoms
Vaginal discharge 165 (74%) 59 (26%) [16]
Intermenstrual bleeding 197 (88%) 27 (12%) [6]
Dyspareunia 207 (92%) 17 (8%) [3]649MJA 197 (11/12) · 3/17 December 2012
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old for diagnosis and treatment. It
may also reduce the extent of delayed
care which is associated with an
increased risk of infertility and
ectopic pregnancy.21
We acknowledge the broader chal-
lenges of working in remote primary
care; the frequent staff turnover and
multiple competing health priorities
are well documented and have
undoubtedly contributed to the gaps
in PID management that we have
identified. We suggest developing fur-
ther clinical decision support in the
form of pathways for the manage-
ment of lower abdominal pain. In
addition, the recent development of
prompts and automated pathology
and treatment pathways for PID
within the patient management sys-
tems in the NT may also lead to
improved management.
It is important to note that we did
not review cases in which lower
abdominal pain was not mentioned in
the medical records. Some of these
may have been additional missed
opportunities for PID diagnosis. Fur-
thermore, we assessed management
as documented in the medical record,
so did not record care that was pro-
vided but not documented. These
methodological limitations mean that
our findings should be interpreted
with a degree of caution, even though
they appear to be strong.
Ultimately, an improved ability to
detect and manage PID in remote
communities will reduce the high rate
of hospitalisation for acute PID
among Aboriginal women in the NT,
and contribute to reducing serious
reproductive sequelae. This change
will require increased awareness,
symptom recognition and revision of
the current guidelines10 to reflect the
reality of the remote situation. In
addition, improving access to and
delivery of a comprehensive sexual
health program to help prevent bacte-
rial STIs is imperative if we are to
reduce the extent of PID. Until this is
achieved, the reproductive health of
Aboriginal women in central Australia
will continue to be at risk.
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